Industry news that matters to you.  Learn more

Meta-Analysis Confirms Link Between Epigenetic Changes and Prostate Cancer

The discovery of effective biomarkers in cancer will have a significant impact on disease management. With the role of the blood-based prostate cancer biomarker PSA (prostate specific antigen) surrounded by controversy, new and more effective biomarkers of this leading cause of death in men are urgently needed. Epigenetic changes are closely linked to cancer and hold promise for prostate cancer diagnosis and management, the authors of a meta-analysis, published online in the leading urology journal, The Prostate, have concluded.

Cancer Biomarker Study Data Presented at the 2011 AACR Meeting

A roundup of five research studies on cancer biomarkers that were presented earlier this week at the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Florida.

Epigenomics and Predictive Biosciences Extend Licensing Deal for Prostate Cancer Test

Epigenomics AG, the cancer diagnostics company, and Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, today announced that they have extended their licensing agreement for the prostate cancer biomarker GSTP1, originally signed in April 2009. Under the terms of the original agreement, Predictive Biosciences had obtained rights to develop a prostate cancer test incorporating this well known DNA methylation biomarker and an option to license GSTP1 for commercialization of this test as a laboratory service in the United States. Based on strong continued progress in developing the test, Predictive Biosciences has now executed this option, triggering an undisclosed one-time license fee to Epigenomics. Epigenomics will also be entitled to royalties on future sales generated with Predictive Biosciences’ prostate cancer test, which is still in development.